BioCentury | May 1, 2020
Distillery Therapeutics

A low-density lipoprotein receptor identified as tauopathy target

DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the low-density lipoprotein receptor LRP1 could treat tauopathies such as Alzheimer’s disease, frontotemporal dementia and chronic traumatic encephalopathy. In a human neuroglioma cell line, CRISPR-mediated inhibition of LRP1 blocked...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge...
...preclinical testing for multiple cancers. TARGET/MARKER/PATHWAY: Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; GPR49); low-density lipoprotein receptor-related protein 6 (LRP6...
...Systemic Hedgehog Pathway Inhibitor) Free University of Brussels Genentech Inc. Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) (GPR49) Low-density lipoprotein receptor-related protein 6 (LRP6) Porcupine...
BioCentury | Aug 30, 2018
Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
BioCentury | Jul 20, 2018
Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
BioCentury | Nov 3, 2017
Product Development

Liver X factor

Rgenix Inc. is preparing to test its RGX-104 in combination with checkpoint inhibitors after Phase I data confirmed the company’s belief that the liver X receptor agonist depletes suppressive immune cells and increases T cell...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
BioCentury | Dec 7, 2015
Clinical News

ANG1005: Interim Phase II data

Interim data from 21 heavily pre-treated breast cancer patients with leptomeningeal carcinomatosis in an open-label, U.S. Phase II trial showed that ANG1005 led to 5 partial responses and 11 cases of stable disease as best...
BioCentury | Jan 5, 2015
Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
BioCentury | Jun 16, 2014
Regulation

Signal crossing

FDA 's workshop on neurological symptoms in inborn errors of metabolism revealed conflicts between how caregivers would like symptoms assessed and what drug companies need to test to get therapies approved. The June 10 workshop...
Items per page:
1 - 10 of 117